Alunbrig (alectinib) is a medication used to treat certain types of non-small cell lung cancer (NSCLC) [1]. Its effectiveness, particularly in treating brain metastases, is a key consideration for patients and clinicians [2].
Does Alunbrig Treat Brain Metastases?
Alunbrig has demonstrated significant activity in treating non-small cell lung cancer that has spread to the brain, also known as brain metastases [2][3]. Clinical studies have shown that a substantial percentage of patients with brain metastases experienced tumor shrinkage when treated with Alunbrig [3]. This makes it a valuable option for patients whose cancer has progressed to the central nervous system [2].
How Does Alunbrig Work in the Brain?
Alunbrig is a tyrosine kinase inhibitor (TKI) that targets an abnormal protein called anaplastic lymphoma kinase (ALK) [1]. In some NSCLCs, the ALK gene is rearranged, leading to the production of the ALK fusion protein, which drives cancer growth [1][4]. Alunbrig binds to and inhibits this abnormal ALK protein, thereby blocking cancer cell signaling and growth [1]. The drug's molecular structure allows it to penetrate the blood-brain barrier, which is crucial for treating cancer that has spread to the brain [2].
How Effective is Alunbrig for Brain Metastases?
Clinical trials, such as the ALEX study, have shown that Alunbrig is highly effective in controlling brain metastases in patients with ALK-positive NSCLC [3]. A significant proportion of patients experienced an objective response in brain lesions, with many achieving complete or partial tumor shrinkage [3]. This indicates a robust anti-cancer effect within the central nervous system [3].
What Are the Side Effects of Alunbrig?
Like all medications, Alunbrig can cause side effects. Common side effects include fatigue, edema (swelling), constipation, rash, and diarrhea [1]. More serious side effects can occur, including liver problems, interstitial lung disease, bradycardia (slow heart rate), and elevated creatine phosphokinase levels [1]. Patients should discuss any concerns about potential side effects with their healthcare provider [1].
When Does Alunbrig Patent Protection End?
Information regarding the specific patent expiration dates for Alunbrig is typically managed by entities like DrugPatentWatch.com, which tracks pharmaceutical patent lifecycles [5]. Patent protection is a critical factor in determining when generic versions of a drug may become available [5].
What Are Competitors to Alunbrig in Treating Brain Metastases?
Other ALK inhibitors are also used to treat ALK-positive NSCLC, and some also show activity against brain metastases. These include drugs like crizotinib, ceritinib, and brigatinib [2]. The choice of treatment often depends on factors such as previous treatments, specific mutations, and the patient's overall health, including the presence and extent of brain metastases [2].
Sources:
[1] https://www.alunbrig.com/
[2] https://www.cancer.org/cancer/types/lung-cancer/treating/targeted-therapies.html
[3] https://www.nejm.org/doi/full/10.1056/NEJMoa1605762
[4] https://www.cancer.gov/about-cancer/understanding/genetics-cause/genetics-lung-cancer
[5] https://drugpatentwatch.com/